MedTrace Logo

Biomarkers in Alzheimer's and Parkinson's Diseases for IA

NCT07651085 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 65

Last updated 2026-06-16

No results posted yet for this study

Summary

Investigate whether endogenous and exogenous risk factors, the presence of pathological amyloid aggregates and alpha-synuclein in the CSF, brain connectivity, and some clinical and biological indices such as vigilance, general motility, the sleep-wake cycle, genomic instability and possible DNA damage may correlate with (or predict) the clinical condition of mild cognitive impairment (MCI) and dementia in patients with Alzheimer's disease (AD) and Parkinson's disease (PD).

Conditions

Interventions

DIAGNOSTIC_TEST

Neuropsycological assesment

Administration of Cognitive and Behavioral Tests

RADIATION

cerebral MRI

Brain connectivity assessed through MRI biomarkers

OTHER

EEG

Brain connectivity assessed through EEG biomarkers

BIOLOGICAL

Venous blood sample of 20ml

Venous blood sample of 20ml

BIOLOGICAL

Sample collection of exfoliated buccal mucosa

Sample collection of exfoliated buccal mucosa

DEVICE

Telemonitoring at home for 1 week

Patients are trained in the correct use of home telemonitoring devices. The staff will guide the patient in the use of the devices, training him in the autonomous management of the instruments. The devices delivered to each patient will be the Samsung Galaxy4 smartwatch, and a Samsung tablet with the serious games SMARTME\&YOU video game application installed.

Sponsors & Collaborators

  • University of Roma La Sapienza

    collaborator OTHER

  • Azienda Ospedaliera di Padova

    collaborator OTHER

  • Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona

    collaborator OTHER

  • IRCCS San Raffaele Roma

    lead OTHER

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-08
Primary Completion
2026-05-19
Completion
2027-07-20

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07651085 on ClinicalTrials.gov